Pancreatic Cancer Research

ResearcherChinese PLA General HospitalNo recent work listed

Shunchang Jiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9184-082X; OpenAlex author ID A5046525642. Sources: ClinicalTrials.gov.

Their work

Papers
3 (first author 1, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
6
Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper

Papers 3

  1. Leukemia-related protein 16 (LRP16) promotes tumor growth and metastasis in pancreatic cancer. Last author DOI 10.2147/ott.s157914↗
  2. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. First author DOI 10.1007/s13277-013-1306-x↗
  3. Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report. Last author DOI 10.3892/ol.2014.1908↗

Trials 1

  1. Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure Principal investigator NCT01219192↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minggen Hu · 1 shared paper, 2018 · strength 0.10
  2. Mo Zheng · 1 shared paper, 2018 · strength 0.10
  3. Yu Wang · 1 shared paper, 2014 · strength 0.06
  4. Yanyan Long · 1 shared paper, 2014 · strength 0.06
  5. Li Bai · 1 shared paper, 2014 · strength 0.05
  6. Dan Su · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.